Published in Nat Genet on July 01, 2008
Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA (2009) 12.35
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Animal models of neuropsychiatric disorders. Nat Neurosci (2010) 5.78
Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry (2009) 4.74
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Meta-analysis in genome-wide association studies. Pharmacogenomics (2009) 3.39
A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry (2013) 2.93
Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol (2011) 2.85
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2011) 2.70
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull (2008) 2.35
Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PLoS One (2008) 2.22
Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology (2010) 2.20
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry (2012) 2.07
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull (2010) 1.98
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 1.96
HGVbaseG2P: a central genetic association database. Nucleic Acids Res (2008) 1.90
Genome-wide association study of smoking initiation and current smoking. Am J Hum Genet (2009) 1.87
Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies. Eur J Hum Genet (2010) 1.79
Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull (2012) 1.75
Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ (2009) 1.73
The impact of multifunctional genes on "guilt by association" analysis. PLoS One (2011) 1.69
Genetics of psychosis; insights from views across the genome. Hum Genet (2009) 1.68
Genetic and environmental pathways to complex diseases. BMC Syst Biol (2009) 1.67
Animal models of schizophrenia. Br J Pharmacol (2011) 1.60
Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med (2009) 1.60
AutismKB: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res (2011) 1.59
NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull (2012) 1.57
Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet (2013) 1.57
Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull (2010) 1.55
Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One (2013) 1.54
Genotype-phenotype databases: challenges and solutions for the post-genomic era. Nat Rev Genet (2009) 1.52
Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut (2013) 1.51
A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case. Bioinformatics (2009) 1.50
Clock genes control cortical critical period timing. Neuron (2015) 1.50
Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull (2009) 1.47
The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry (2008) 1.47
MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One (2011) 1.47
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth. Mol Psychiatry (2009) 1.44
Analysis of genomic variation in non-coding elements using population-scale sequencing data from the 1000 Genomes Project. Nucleic Acids Res (2011) 1.43
Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus. Front Genet (2013) 1.43
Schizophrenia genetics: where next? Schizophr Bull (2011) 1.42
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry (2011) 1.40
A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol (2010) 1.40
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain (2008) 1.37
SZGR: a comprehensive schizophrenia gene resource. Mol Psychiatry (2010) 1.36
The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet (2009) 1.35
Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci (2012) 1.34
MicroRNA dysregulation in psychiatric disease. Brain Res (2010) 1.34
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 1.33
Tilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causation. Genetics (2008) 1.33
Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. J Neurosci (2010) 1.33
Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci (2009) 1.32
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A (2013) 1.31
Gene Prospector: an evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics (2008) 1.31
MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A (2008) 1.30
Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol Med (2011) 1.30
Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J Psychiatr Res (2010) 1.30
Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav (2009) 1.29
Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting. Front Neural Circuits (2009) 1.28
What we know: findings that every theory of schizophrenia should explain. Schizophr Bull (2009) 1.27
Association between SNPs and gene expression in multiple regions of the human brain. Transl Psychiatry (2012) 1.27
Evaluating historical candidate genes for schizophrenia. Mol Psychiatry (2015) 1.26
AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci (2012) 1.25
Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev (2010) 1.24
Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry (2010) 1.24
Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci (2009) 1.24
Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One (2010) 1.24
Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol (2012) 1.23
Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry (2013) 1.22
The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am (2010) 1.22
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
The serotonin transporter gene and risk for alcohol dependence: a meta-analytic review. Drug Alcohol Depend (2010) 1.19
Knowledge integration in cancer: current landscape and future prospects. Cancer Epidemiol Biomarkers Prev (2012) 1.19
Understanding the complex etiologies of developmental disorders: behavioral and molecular genetic approaches. J Dev Behav Pediatr (2010) 1.18
Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1. J Neurosci (2012) 1.18
Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet (2009) 1.18
Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. Biol Psychiatry (2011) 1.18
Genome-wide association studies: a primer. Psychol Med (2009) 1.16
Multifaceted genomic risk for brain function in schizophrenia. Neuroimage (2012) 1.16
Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system. Mol Psychiatry (2013) 1.16
Genome-wide scan for signatures of human population differentiation and their relationship with natural selection, functional pathways and diseases. PLoS One (2009) 1.14
A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst Biol (2011) 1.13
Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron (2014) 1.13
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol (2012) 1.12
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry (2009) 1.12
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A (2012) 1.12
Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod (2011) 1.12
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci (2013) 1.12
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.11
Quaking regulates Hnrnpa1 expression through its 3' UTR in oligodendrocyte precursor cells. PLoS Genet (2011) 1.11
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol (2014) 1.11
Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proc Natl Acad Sci U S A (2008) 1.10
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry (2010) 1.10
Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE)-a suitable endophenotype of schizophrenia. Front Hum Neurosci (2013) 1.10
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
A common genetic variant is associated with adult and childhood obesity. Science (2006) 14.95
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci (2013) 13.37
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Letting the genome out of the bottle--will we get our wish? N Engl J Med (2008) 9.10
Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med (2011) 8.48
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
The case of the misleading funnel plot. BMJ (2006) 8.26
Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol (2006) 7.66
Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ (2014) 7.21
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol (2008) 5.88
Research grants: Conform and be funded. Nature (2012) 5.83
Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA (2002) 5.81
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
Assessment of claims of improved prediction beyond the Framingham risk score. JAMA (2009) 5.36
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Why current publication practices may distort science. PLoS Med (2008) 5.09
A navigator for human genome epidemiology. Nat Genet (2008) 5.07
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91
Evaluation of networks of randomized trials. Stat Methods Med Res (2007) 4.70
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet (2003) 4.58
Number of published systematic reviews and global burden of disease: database analysis. BMJ (2003) 4.53
Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol (2008) 4.53
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005) 4.48
How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol (2005) 4.46
Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol (2005) 4.45
Public availability of published research data in high-impact journals. PLoS One (2011) 4.41
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2011) 4.22
Relative citation impact of various study designs in the health sciences. JAMA (2005) 4.19
Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ (2012) 4.16
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol (2010) 4.10
The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol (2010) 4.04
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Hum Genet (2007) 3.92
Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med (2011) 3.81
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ (2002) 3.78
Can family history be used as a tool for public health and preventive medicine? Genet Med (2002) 3.76
Translation of highly promising basic science research into clinical applications. Am J Med (2003) 3.74
National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health (2012) 3.72
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Overlapping meta-analyses on the same topic: survey of published studies. BMJ (2013) 3.57
Empirical evaluation of very large treatment effects of medical interventions. JAMA (2012) 3.48
Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet (2012) 3.48
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst (2005) 3.41
Meta-analysis in genome-wide association studies. Pharmacogenomics (2009) 3.39
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol (2004) 3.28
A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet (2008) 3.25
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Medicine. Life cycle of translational research for medical interventions. Science (2008) 3.12
What is the clinical utility of genetic testing? Genet Med (2006) 3.01
Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet (2003) 3.00
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med (2003) 2.99
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst (2006) 2.91
HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics (2005) 2.81
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Improving validation practices in "omics" research. Science (2011) 2.73
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66